New Study Reveals UltraSight & Sheba Medical Center Enable Novice Ultrasound Users to Obtain Accurate, Diagnostic Quality Cardiac Images

UltraSight reports at the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, and Sheba Medical Center Israel revealed new research findings from a blinded pilot study that validates the company’s technology, and confirms that UltraSight’s Artificial Intelligence (AI) guidance can allow any medical professional to successfully capture quality cardiac ultrasound images.

Led by Prof. Robert Klempfner MD, Director of the Cardiac Rehabilitation Institute at the Sheba Medical Center Israel and the Scientific Director of Big Data and AI at the hospital’s ARC Innovation Center, the study evaluated the 2D transthoracic echocardiography (TTE) images taken by medical assistants using UltraSight’s AI real-time guidance software. According to the results, UltraSight is effective at instructing novice medical professionals to acquire diagnostic quality exams in cardiac patients. Furthermore, the study concluded that UltraSight AI guidance can allow medical professionals, who do not have prior sonography training, to obtain diagnostic quality cardiac images in 100 percent of patients.

“Cardiac ultrasound is a powerful diagnostic tool enabling timely evaluation of a patient in the emergency department,” said Davidi Vortman, CEO of UltraSight. “However, its application is often limited by the availability of experienced users. This study is a significant step forward in making cardiac ultrasound more widely accessible to patients anywhere.”

For the study, three novice medical assistants, none of which who had any cardiac ultrasound experience, underwent an eight-hour training course before scanning 61 cardiac patients in all 10 standard echocardiography views. These patients were also scanned by a trained sonographer, and each exam was evaluated by three blinded USA board-certified cardiologists who scored the images for diagnostic quality. The medical assistants’ exams successfully permitted the assessment of left ventricular size and function, right ventricular size, and presence of significant pericardial effusion.

“These anatomical assessments are essential to determining heart pathologies,” said Prof. Roberto M Lang MD, Director Noninvasive Cardiac Imaging Laboratory at the University of Chicago. “This is crucial in critical care settings and emergency departments where decisions about cardiac treatment and care need to be made very quickly before conditions deteriorate. The fact that medical assistants were able to take such precise images and achieve near-perfect results with a handheld device is outstanding.”

“UltraSight’s novel technology enables novice users, after minimal training, to perform high quality diagnostic echocardiographic studies,” said Prof. Klempfner. “The technology has the potential to increase user adoption of point of care ultrasound and accelerate patient care in a variety of clinical settings ranging from EMS services, Emergency Medicine to Cardiology and even patient homes.”

UltraSight software pairs with point of care ultrasound devices available today. Using innovative AI algorithms, the software analyzes the ultrasound video stream and provides users with real-time guidance how to maneuver the ultrasound probe and obtain diagnostic quality cardiac ultrasound images.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version